Portrai Insights
Insights on data analysis, AI, and the platform we're building at Portrai.
Latest
4 articles
[Sid’s Data Journey - Part 3] Virtual Tissue Pharmacology: Bringing In Silico Drug Testing to a Patient Tissue
The AI scientist in the loop Two things happen in this part. We turn expression into radiation dose, which is the number aradiopharmaceutical is actually judged on. And we show who did the first vers…
[Sid’s Data Journey - Part 2] Beyond Expression: How to Evaluate Drug Targets
Does it hit every cancer cell A target that reaches only a fraction of a tumour inevitably leaves part of it behind. That is why coverage—the fraction of cancer cells expressing a target—is one of th…
[Sid’s Data Journey - Part 1] Single-Patient PortraiTARGET: Data-Driven Target Discovery for Personalized Drug Development
One patient is a dataset single-patient target discovery with PortraiTARGET Portrai is building PortraiTARGET, a platform designed to identify the best targets for cancerdrugs by analyzing large-scal…
Target-based Understanding the Termination of the AMG 794 Clinical Trial: A Deep Dive with spatial transcriptomics data
Amgen has exited the competitive development of Claudin 6 (CLDN6) therapies, which is still in its early stages, based on initial data from preclinical studies. Amgen, on July 5th 2024, had terminated
WRITTEN BY
Portrai's Authors
Capturing and compounding Portrai's insights.
Daeseung Lee
CEO
Physician-scientist who left clinical practice to bring spatial biology into oncology drug discovery
Hongyoon Choi
CTO
Builds the algorithms that turn spatial transcriptomics into actionable target intelligence
Hyung-Jun Im
CSO
Nuclear medicine specialist linking imaging biomarkers to next-generation radiopharmaceuticals
Kwonjoong Na
CMO
Translates platform insights into IND-enabling decisions across oncology programs
Portrai
Official posts from the Portrai team, decoding disease with spatial intelligence